Keyword: Bristol-Myers Squibb
With a shareholder vote in favor of the BMS-Celgene marriage, the combined company will get its chance to prove it's worth the $74 billion price.
Opdivo, the Bristol-Myers cancer drug co-developed with Japan’s Ono, is a global cash cow—but a Nobel winner behind the drug isn't happy with his cut.
Even as Amgen faces a likely sales decline in 2019, its chief executive earned a 10% raise in 2018.
After a blow in first-line lung cancer, BMS is clinging to its share of the second-line market. And it’s hoping new long-term data can help it hang on.
Recommendations to vote “yes” from proxy advisory firms were enough to end an activist’s efforts to scuttle the BMS-Celgene merger.
Bristol-Myers' Opdivo-Yervoy combo has found success treating various common tumors. But the duo can help some patients with rare tumors, too.
When it comes to Bristol-Myers Squibb’s Celgene merger, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up.
Merck's Keytruda has leaped ahead of Bristol-Myers Squibb’s Opdivo and nabbed a green light in newly diagnosed non-small cell lung cancer.
Turns out shareholders aren’t the only ones who have some issues with Bristol-Myers Squibb’s proposed $74 billion Celgene merger.
Proxy advisers will soon weigh in on BMS' $74 billion Celgene buyout, and their verdicts could sway undecided shareholders, analysts say.